---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-297211"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2026-07-07T16:45:57+00:00"
generated_at: "2026-07-07T16:47:09.155090+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "medium"
source: SEC EDGAR
---

# FDA grants accelerated approval for Vera's TRUTAKNA (atacicept) in IgA nephropathy

## Summary
- FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
- Approval announced on July 7, 2026; this is a significant regulatory milestone for Vera Therapeutics.
- The accelerated approval is based on reduction of proteinuria as a surrogate endpoint.

## SEC filing metadata
- accession: 0001193125-26-297211
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2026-07-07T16:45:57+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312526297211/0001193125-26-297211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312526297211/vera-20260707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-297211
- JSON: https://secwatch.observer/filing/0001193125-26-297211.json
- Plain text: https://secwatch.observer/filing/0001193125-26-297211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.